Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity
After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.
Target cuts top end of annual adjusted profit forecast Adds $1 billion to investment in store remodels, digital sales Shares down about 2.1% Nov 19 (Reuters) - Target (TGT.N), opens new tab reported a ...
For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. The ...
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. The paramilitary force fighting since 2023 to take ...
On October 9, we’ll head back to Septimont, where a new Resonator is on her own hunt, with one of our allies in the crosshairs. Wuthering Waves' latest update will consist of three main story quests, ...
The Trump administration has locked in a 2.6% payment rate increase for inpatient services in the coming fiscal year as well as an industry-opposed mandatory payment model for five common surgical ...
Roche has axed one of the obesity assets from its $2.7 billion Carmot Therapeutics buyout, sending the molecule to the scrap heap months after hyping its potential to drive weight loss past the GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results